(2003; 67 pages)
4.4 Is the problem limited to imported or domestic products?
No significant trend was noted in comparing local versus foreign manufacturers, as shown in Table III. There were failures of 56% (27/48) amongst locally made products, compared to 47.2% (17/36) for foreign products for CQT active ingredient content, and 28% (7/25) versus 13% (3/23) CQS active ingredient content. Further investigation of this phenomenon will be important since it is easier for national drug regulatory authorities to act and correct problems that involve domestic manufacturers.